A six-month shortage of cisplatin, a drug used in the treatment of head and neck cancer, resulted in a 16% total cost increase for practices in the U.S. Oncology Network, according to a study presented Sept. 27-28, at the American Society of Clinical Oncology’s 2024 Quality Care Symposium in San Francisco.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
